#1 Clinical Trials Search in Europe

Hypothalamic Phospholipids

This article discusses a clinical trial investigating the use of Hypothalamic Phospholipids, specifically Liposom Forte, in combination with the antidepressant citalopram for treating Major Depressive Disorder (MDD) in elderly patients. The study aims to determine if Liposom Forte can enhance and speed up the response to antidepressant therapy, potentially offering a more effective treatment option for this vulnerable population.

Table of Contents

What is Liposom Forte?

Liposom Forte is a medication containing hypothalamic phospholipids as its active ingredient. It is administered as an intramuscular injection and is being studied as a potential treatment for major depressive disorder in elderly patients[1]. The drug is manufactured by Fidia Farmaceutici S.P.A and is currently undergoing clinical trials to assess its effectiveness and safety.

Medical Condition Targeted

The primary medical condition targeted by Liposom Forte is Major Depressive Disorder (MDD) in elderly patients[1]. MDD is a serious mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities. It can significantly impact a person’s daily life and overall well-being, especially in older adults.

How Liposom Forte Works

Liposom Forte is being studied as an add-on treatment to enhance and speed up the response to antidepressant therapy with citalopram[1]. While the exact mechanism of action is not fully explained in the provided information, hypothalamic phospholipids are believed to play a role in improving brain function and potentially alleviating depressive symptoms.

Clinical Trial Details

A clinical trial is currently underway to assess the safety and effectiveness of Liposom Forte. Here are some key details about the study:

  • It is a randomized, double-blind, placebo-controlled, multicenter clinical trial[1].
  • Participants receive a daily dose of 10mg of citalopram (an antidepressant) orally for 90 days[1].
  • As an add-on treatment, patients receive either 2 ampoules of Liposom Forte or a placebo, administered as a single intramuscular injection for 30 days[1].
  • The study aims to determine if Liposom Forte can enhance and speed up the response to antidepressant therapy with citalopram[1].

Eligibility Criteria

To participate in the clinical trial, patients must meet certain criteria. Some key inclusion criteria include:

  • Meeting DSM-V criteria for major depressive disorder[1]. (DSM-V is the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, used by mental health professionals to diagnose mental health conditions.)
  • Scoring 16 or higher on the HAM-D (Hamilton Depression Rating Scale)[1]. This scale is used to assess the severity of depression symptoms.
  • Scoring 23 or higher on the Mini-Mental State Exam (MMSE-2)[1]. This test is used to evaluate cognitive function in older adults.

There are also several exclusion criteria, such as having certain medical conditions or taking specific medications that could interfere with the study results or pose safety risks[1].

Potential Benefits

The clinical trial aims to assess several potential benefits of Liposom Forte, including:

  • Improvement of depressive symptoms, measured using the Hamilton Rating Scale for Depression (HAM-D)[1].
  • Faster response to antidepressant therapy[1].
  • Overall improvement in clinical condition, assessed using the Clinical Global Impression (CGI) score[1].

Safety Considerations

As with any medication, safety is a crucial aspect of the clinical trial. The study will assess the safety of Liposom Forte by:

  • Tracking adverse events (side effects) throughout the study period[1].
  • Monitoring vital signs and conducting ECG (electrocardiogram) measurements[1].

It’s important to note that Liposom Forte is still being studied, and its full safety profile and effectiveness are not yet established. Patients should always consult with their healthcare provider before considering any new treatments or participating in clinical trials.

Aspect Details
Study Type Randomized, double-blind, placebo-controlled, multicenter clinical trial
Primary Objective Assess safety and effectiveness of Liposom Forte in enhancing antidepressant therapy with citalopram
Target Population Elderly patients with Major Depressive Disorder (MDD)
Treatment Duration 90 days
Intervention Liposom Forte (2 ampoules of 28mg/2 ml) + citalopram (10mg) vs. Placebo + citalopram (10mg)
Primary Outcome Measure Change in Hamilton Rating Scale for Depression (HAM-D) score at day 30
Key Secondary Outcomes Speed of response, percentage of responders, Clinical Global Impression
Safety Assessments Adverse events tracking, ECG, vital signs measurements

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to determine if Liposom Forte (Hypothalamic Phospholipids) can enhance the response to antidepressant therapy with citalopram in elderly patients suffering from Major Depressive Disorder (MDD).
  • Who can participate in this study? Elderly patients who meet the criteria for major depressive disorder, have a score of 16 or higher on the Hamilton Rating Scale for Depression (HAM-D), and a score of 23 or higher on the Mini-Mental State Exam (MMSE-2) may be eligible to participate. However, there are several exclusion criteria, such as having other psychiatric disorders or certain medical conditions.
  • How long does the treatment last in this trial? The treatment period lasts for 90 days. Participants receive a daily dose of 10mg citalopram throughout the trial. Additionally, they receive either Liposom Forte or a placebo as an intramuscular injection for the first 30 days of the study.
  • What are the main outcomes being measured in this study? The primary outcome is the improvement of depressive symptoms after 30 days, measured using the Hamilton Rating Scale for Depression. Secondary outcomes include the speed of response to treatment, the percentage of patients responding to treatment, and overall clinical improvement as assessed by the Clinical Global Impression scale.
  • Are there any safety measures in place during the trial? Yes, the study includes safety assessments throughout the trial period. Adverse events are tracked at each visit, and ECG and vital signs measurements are taken to monitor participants' health and well-being.

Ongoing Clinical Trials on Hypothalamic Phospholipids

  • Study on the Effectiveness of Hypothalamic Phospholipids and Citalopram for Treating Major Depressive Disorder in Elderly Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities, which significantly impact daily life and functioning.
  • Hypothalamic Phospholipids: The active ingredient in Liposom Forte, which is being studied for its potential to enhance antidepressant therapy.
  • Citalopram: An antidepressant medication belonging to the selective serotonin reuptake inhibitor (SSRI) class, used to treat depression.
  • Hamilton Rating Scale for Depression (HAM-D): A standardized questionnaire used by healthcare professionals to assess the severity of depression symptoms.
  • Mini-Mental State Exam (MMSE-2): A brief test used to screen for cognitive impairment and assess mental status in older adults.
  • Clinical Global Impression (CGI): A scale used by healthcare providers to evaluate the overall severity of a patient's condition and their response to treatment.
  • Placebo: An inactive substance that looks like the real medication but contains no active ingredients, used to compare the effects of the actual treatment.
  • Double-blind study: A research design where neither the participants nor the researchers directly involved know who is receiving the actual treatment and who is receiving the placebo.
  • Intramuscular injection: A method of administering medication by injecting it directly into a muscle.
  • Adverse events: Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-hypothalamic-phospholipids-and-citalopram-for-treating-major-depressive-disorder-in-elderly-patients/